Cancer Pain – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cancer Pain – Pipeline Review, H1 2018’, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cancer Pain

– The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects

– The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cancer Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cancer Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexza Pharmaceuticals Inc

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

AstraZeneca Plc

ChironWells GmbH

Colby Pharmaceutical Co

Daewoong Pharmaceutical Co Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Immupharma Plc

Insys Therapeutics Inc

IntelGenx Corp

iX Biopharma Ltd

Klaria Pharma Holding AB

Komipharm International Co Ltd

Medlab Clinical Ltd

Nanomerics Ltd

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Orion Corporation

Pain Therapeutics Inc

Pfizer Inc

Pharmaleads SA

Plexxikon Inc

Recordati SpA

Ribomic Inc

Tetra Bio-Pharma Inc

Virobay Inc

WEX Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cancer Pain Overview

Cancer Pain Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cancer Pain Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cancer Pain Companies Involved in Therapeutics Development

Alexza Pharmaceuticals Inc

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

AstraZeneca Plc

ChironWells GmbH

Colby Pharmaceutical Co

Daewoong Pharmaceutical Co Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Immupharma Plc

Insys Therapeutics Inc

IntelGenx Corp

iX Biopharma Ltd

Klaria Pharma Holding AB

Komipharm International Co Ltd

Medlab Clinical Ltd

Nanomerics Ltd

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Orion Corporation

Pain Therapeutics Inc

Pfizer Inc

Pharmaleads SA

Plexxikon Inc

Recordati SpA

Ribomic Inc

Tetra Bio-Pharma Inc

Virobay Inc

WEX Pharmaceuticals Inc

Cancer Pain Drug Profiles

(fentanyl + menthol) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(fentanyl + naloxone) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-2002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-118 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-8797 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cannabis Intractable Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexmedetomidine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Cancer Neuropathic Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-208 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fentanyl Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fentanyl citrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fentanyl citrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fentanyl citrate ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabapentin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-3150 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-198 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HYLP-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPP-102199 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-00406 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methadone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TRPV1 for Cancer Pain and Inflammatory Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-127 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAX-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-37 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPP-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QX-314 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiniferatoxin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetrodotoxin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tilidine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOT-303 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer Pain Dormant Projects

Cancer Pain Discontinued Products

Cancer Pain Product Development Milestones

Featured News & Press Releases

Feb 04, 2018: Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval for Smokable Dried Cannabis Prescription Drug

Sep 28, 2017: Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

Sep 11, 2017: Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567

Jul 18, 2017: Hisamitsu Pharmaceutical Announces Commencement of the Phase III clinical study of HP-3150 in Japan for “cancer pain”

Jun 07, 2017: Tetra Bio-Pharma Announces the Completion of its Phase 1 Safety Report to Health Canada and Launches the Preparation of a Phase III Clinical Trial for PPP001 with Sante Cannabis

May 09, 2017: Kancera Announces Approval For The Start Of Clinical Trial Of KAND567

Apr 19, 2017: Kancera has applied for a clinical trial for KAND567

Feb 23, 2017: Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)

Feb 16, 2017: Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

Jan 30, 2017: Tetra Bio-Pharma Completes Pre-IND Meeting with Food and Drug Administration on PPP001

Nov 02, 2016: Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board

Sep 30, 2016: Grunenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain

Sep 26, 2016: PhytoPain Pharma Provides USA Regulatory Update for Its Cannabis Inhalation Product PPP001

Aug 29, 2016: Hisamitsu Pharmaceutical Announces the results of the Phase II / III clinical study of HP-3150 in Japan for “ cancer pain”(an analgesic transdermal drug containing NSAIDs)

Sep 08, 2015: Kancera evaluates immuno-oncology drug candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cancer Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cancer Pain Pipeline by Alexza Pharmaceuticals Inc, H1 2018

Cancer Pain Pipeline by AngioChem Inc, H1 2018

Cancer Pain Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018

Cancer Pain Pipeline by Aphios Corp, H1 2018

Cancer Pain Pipeline by AstraZeneca Plc, H1 2018

Cancer Pain Pipeline by ChironWells GmbH, H1 2018

Cancer Pain Pipeline by Colby Pharmaceutical Co, H1 2018

Cancer Pain Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Cancer Pain Pipeline by Dompe Farmaceutici SpA, H1 2018

Cancer Pain Pipeline by Fujimoto Pharmaceutical Corp, H1 2018

Cancer Pain Pipeline by Grunenthal GmbH, H1 2018

Cancer Pain Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2018

Cancer Pain Pipeline by Immupharma Plc, H1 2018

Cancer Pain Pipeline by Insys Therapeutics Inc, H1 2018

Cancer Pain Pipeline by IntelGenx Corp, H1 2018

Cancer Pain Pipeline by iX Biopharma Ltd, H1 2018

Cancer Pain Pipeline by Klaria Pharma Holding AB, H1 2018

Cancer Pain Pipeline by Komipharm International Co Ltd, H1 2018

Cancer Pain Pipeline by Medlab Clinical Ltd, H1 2018

Cancer Pain Pipeline by Nanomerics Ltd, H1 2018

Cancer Pain Pipeline by Neurocentrx Pharma Ltd, H1 2018

Cancer Pain Pipeline by Nippon Kayaku Co Ltd, H1 2018

Cancer Pain Pipeline by Orion Corporation, H1 2018

Cancer Pain Pipeline by Pain Therapeutics Inc, H1 2018

Cancer Pain Pipeline by Pfizer Inc, H1 2018

Cancer Pain Pipeline by Pharmaleads SA, H1 2018

Cancer Pain Pipeline by Plexxikon Inc, H1 2018

Cancer Pain Pipeline by Recordati SpA, H1 2018

Cancer Pain Pipeline by Ribomic Inc, H1 2018

Cancer Pain Pipeline by Tetra Bio-Pharma Inc, H1 2018

Cancer Pain Pipeline by Virobay Inc, H1 2018

Cancer Pain Pipeline by WEX Pharmaceuticals Inc, H1 2018

Cancer Pain Dormant Projects, H1 2018

Cancer Pain Dormant Projects, H1 2018 (Contd..1), H1 2018

Cancer Pain Dormant Projects, H1 2018 (Contd..2), H1 2018

Cancer Pain Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Cancer Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports